Scarica l'app Stockscreener
21.01
0.10%
-0.02
Dopo l'orario di chiusura:
21.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Precedente Chiudi:
$21.03
Aprire:
$21.12
Volume 24 ore:
1.05M
Relative Volume:
0.88
Capitalizzazione di mercato:
$2.56B
Reddito:
$460.48M
Utile/perdita netta:
$142.80M
Rapporto P/E:
17.81
EPS:
1.18
Flusso di cassa netto:
$221.79M
1 W Prestazione:
-2.82%
1M Prestazione:
-6.54%
6M Prestazione:
-8.33%
1 anno Prestazione:
+24.03%
Intervallo 1D:
$20.95
$21.42
Intervallo di 1 settimana:
$20.60
$21.78
Portata 52W:
$15.34
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Nome
Catalyst Pharmaceuticals Inc
Settore
Industria
Telefono
(305) 529-2522
Indirizzo
355 ALHAMBRA CIRCLE, CORAL GABLES
Confronta CPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.01 | 2.64B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-03-14 | Iniziato | Citigroup | Buy |
| 2024-03-07 | Iniziato | BofA Securities | Buy |
| 2023-12-21 | Iniziato | Oppenheimer | Outperform |
| 2022-08-24 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Ripresa | Piper Jaffray | Overweight |
| 2016-10-05 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Reiterato | ROTH Capital | Buy |
| 2014-09-16 | Reiterato | ROTH Capital | Buy |
| 2014-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2013-10-21 | Reiterato | Aegis Capital | Buy |
| 2013-09-24 | Iniziato | Maxim Group | Buy |
| 2013-09-06 | Reiterato | Aegis Capital | Buy |
| 2013-04-18 | Iniziato | Aegis Capital | Buy |
| 2012-08-27 | Aggiornamento | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Aggiornamento | Merriman | Sell → Neutral |
| 2009-05-29 | Downgrade | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Iniziato | Merriman Curhan Ford | Buy |
| 2007-11-28 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Iniziato | Stifel Nicolaus | Buy |
| 2007-01-05 | Iniziato | First Albany | Buy |
Mostra tutto
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
What drives Catalyst Pharmaceuticals Inc. stock priceHigh-octane financial growth - Autocar Professional
What analysts say about Catalyst Pharmaceuticals Inc. stockOverwhelming financial success - jammulinksnews.com
Is Catalyst Pharmaceuticals Inc. a good long term investmentLightning-fast growth - jammulinksnews.com
Catalyst Pharmaceuticals Inc. Stock Analysis and ForecastExceptional profit margins - jammulinksnews.com
Why Catalyst Pharmaceuticals Inc. stock is on top investor watchlistsSafe and Smart Investment Picks - Newser
Published on: 2025-07-17 22:44:23 - Newser
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo.co
Teacher Retirement System of Texas Sells 2,766 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
What makes Catalyst Pharmaceuticals Inc. stock price move sharplyFree Stock Tips Group - beatles.ru
Why Catalyst Pharmaceuticals Inc. stock attracts strong analyst attentionPro Trader Stock Focus - Newser
How Catalyst Pharmaceuticals Inc. stock performs during market volatilityRisk Aware High Growth Picks - Newser
Principal Financial Group Inc. Purchases 17,018 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Amalgamated Bank Decreases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Cambridge Investment Research Advisors Inc. Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
GAMMA Investing LLC Acquires 579 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Institutional investors in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) lost 3.5% last week but have reaped the benefits of longer-term growth - simplywall.st
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by New York State Teachers Retirement System - Defense World
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Allspring Global Investments Holdings LLC Sells 244,148 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals is Now Oversold (CPRX) - Nasdaq
Top 3 Health Care Stocks You'll Regret Missing This Quarter - inkl
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Nasdaq
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Reports Strong Q1 2025 Earnings Growth - Yahoo Finance
Stanley Laman Group Ltd. Acquires New Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
GAMMA Investing LLC Has $1.64 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading Down 5.2% Following Insider Selling - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $42,272.00 in Stock - MarketBeat
Trading (CPRX) With Integrated Risk Controls - news.stocktradersdaily.com
Preethi Sundaram Implements A Sell Strategy: Offloads $103K In Catalyst Pharmaceuticals Stock - Nasdaq
Insider Sell: Preethi Sundaram Sells Shares of Catalyst Pharmaceuticals Inc (CPRX) - GuruFocus
Preethi Sundaram Sells 2,324 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - MarketBeat
117,374 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Bought by Bridge City Capital LLC - MarketBeat
Director Of Catalyst Pharmaceuticals Sold $5.22M In Stock - Nasdaq
Strong Inflows Make Catalyst Stock an Outlier - FXEmpire
Insider Sell: Patrick Mcenany Sells 200,000 Shares of Catalyst P - GuruFocus
Catalyst Pharmaceuticals, Inc. (CPRX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Catalyst Pharmaceuticals stock soars to all-time high of $26.49 By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals stock soars to all-time high of $26.49 - Investing.com Australia
Catalyst Pharmaceuticals Inc Azioni (CPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):